CoChat

Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study

Open access
Oral, Alihan, Küçük, Celalettin, Köse, Murat · 2024 · Journal of Clinical Medicine

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Introduction: Obesity is a complicated chronic disease associated with a series of other conditions. A weight loss of 5–10% has been shown to reduce obesity-related complications and improve quality of life. The efficacy and safety of liraglutide for reducing body weight have been demonstrated in clinical trials. This study evaluated the weight loss efficacy and adverse effects of liraglutide in those with obesity in the Turkish population. Methods: This is a retrospective cohort study; the patients that were included had a body mass index (BMI) of 27 or greater with additional comorbidities or a BMI of 30 or greater, and the patients were prescribed liraglutide for obesity treatment from the tertiary private clinic between January 2022 and January 2024. Their metabolic and anthropometric parameters were recorded at the initial appointment, and their body weight and adverse effects were followed up on during therapy. Results: For the 568 patients, of whom 487 (85.6%) were female, the mean values for age, weight, and BMI were 42.37 ± 10.50, 98.09 ± 17.48 kg, and 35.77 ± 5.45 kg/m2, respectively. Reductions in body weight at the 4th, 8th, 12th, and 24th weeks were 6.45 ± 2.32 kg, 10.66 ± 3.41 kg, 15.38 ± 8.30 kg, and 19 ± 9.06 kg, respectively; reductions in BMI at the 4th, 8th, 12th, and 24th weeks were 2.36 ± 1.00, 3.88 ± 1.25, 5.36 ± 1.76, and 7.09 ± 2.93, respectively; and the percentages of overall body weight loss at the 4th, 8th, 12th, and 24th weeks were 6.62 ± 2.1%, 10.75 ± 2.71%, 14.97 ± 6.8%, and 18.55 ± 4.63%, respectively (all p values < 0.0001). The percentage of patients who lost more than 5% and more than 10% of their initial weight was 100% at the 24th week. The most common side effect was nausea; no pancreatitis was observed. Conclusions: The results of our study indicate that liraglutide is an efficacious and safe treatment option for obesity in the Turkish population, in accordance with the findings from previous research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm13206121

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of the number of patients included in the study. SGLT2, sodium–glucose cotransporter-2 inhibitors; SSRIs, selective serotonin reuptake inhibitors.
Figure 1 Flowchart of the number of patients included in the study. SGLT2, sodium–glucose cotransporter-2 inhibitors; SSRIs, selective serotonin reuptake inhibitors.CC BY · PubMed Central
Figure 2 Body weight at initial appointment and at follow-up.
Figure 2 Body weight at initial appointment and at follow-up.CC BY · PubMed Central
Figure 3 Body weight change at initial appointment and at follow-up.
Figure 3 Body weight change at initial appointment and at follow-up.CC BY · PubMed Central
Figure 4 Body weight change compared to initial weight.
Figure 4 Body weight change compared to initial weight.CC BY · PubMed Central
Figure 5 Body mass index at baseline and at follow-up.
Figure 5 Body mass index at baseline and at follow-up.CC BY · PubMed Central
Figure 6 Change in BMI at follow-up.
Figure 6 Change in BMI at follow-up.CC BY · PubMed Central
Figure 7 The impact of confounding factors on weight loss. (A) gender: p = 0.074, (B) diabetes mellitus: p = 0.451, (C) hypertension: p = 0.730, and (D) age: p = 0.673.
Figure 7 The impact of confounding factors on weight loss. (A) gender: p = 0.074, (B) diabetes mellitus: p = 0.451, (C) hypertension: p = 0.730, and (D) age: p = 0.673.CC BY · PubMed Central
Figure 8 The proportion of patients who achieved weight loss of at least 5% and at least 10% of initial weight.
Figure 8 The proportion of patients who achieved weight loss of at least 5% and at least 10% of initial weight.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Tor, 2023, Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması, Sakarya Tıp. Dergisi., 13, 334

Cited by

See all 8

Metadata

Authors
Oral, A., Küçük, C., & Köse, M.
Affiliations
  • Biruni University (TR)
  • Istanbul University (TR)
Corresponding author
Oral, Alihan
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2024-10-14
Volume
13
Issue
20
Pages
6121
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4403605864
Cited by
8
References
23
Citations by year
2026: 4 · 2025: 4
FWCI
2.26
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
liraglutide, obesity, weight loss, GLP-1 receptor agonists, real-world effectiveness, adverse effects, gastrointestinal adverse effects, body mass index, Turkish patients, obesity-related comorbidities, patient satisfaction, quality of life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. https://app.cochat.ai/papers/10.3390/jcm13206121
The paper
Oral, A., Küçük, C., & Köse, M. (2024). Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13206121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.